Performance highlights designed for the Quarter ended 30th June, 2009

Performance highlights designed for the Quarter ended 30th June, 2009

· Net sales up by 39% to Rs. 127.3 crore as compared to Rs. 91.9 crore in the corresponding quarter of the prior time.

· PAT has risen by 25% to Rs. 13.3 crore from Rs.10.6 crore in the corresponding quarter of the prior time later as long as Rs.8.54 crore towards foreign discussion contracts with the intention of were established in the quarter.

· Crop protection sales up by 29% to Rs. 41.1 crore as compared to Rs. 31.8 crore in the corresponding quarter of the prior time.

· Pharmaceutical sales up by 43% to Rs. 86.1 crore as compared to Rs. 60.1 crore in the corresponding quarter of the prior time.

Commenting on the results, Mr. Jai Hiremath, Vice Chairman & Managing Director, Hikal Ltd. Assumed, “We take part in had a useful start to this economic time. Our Net sales are up by 39%. Our pharmaceutical issue has registered a substantial growth of 43% and the crop protection issue has developed by 29% this quarter. Due to the office expansions concluded keep on time we expect continued growth in the next quarters. Despite the adverse money-making place, we take part in maintained even growth in revenue and profits.”

- End -

About Hikal:

Hikal is a dependable long-term outsourcing partner to companies in the Pharmaceuticals, Crop protection Products, and Specialty Chemicals industry. The company has been supplying source working ingredients (AI) and intermediates, manufactured using stringent inclusive quality values, designed for its customers in the United States, Europe and Japan. Hikal’s forward-thinking manufacturing facilities take part in been inspected and permitted by leading inclusive players in Crop protection and Pharmaceutical sectors. The crop protection facilities are located by the side of Taloja and Mahad (Maharashtra). Hikal’s manufacturing activities are supported by state-of-the-art follow a line of investigation centres and pilot yard facilities located by the side of Bangalore and Taloja correspondingly. The API and pharmaceutical intermediates manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat), correspondingly